Results 171 to 180 of about 63,782 (312)

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

When help is harm. [PDF]

open access: yesSci Adv
Farris AD, Jupudi AA.
europepmc   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

open access: yesPhytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee   +9 more
wiley   +1 more source

Photo‐responsive carbon dots for pyroptosis‐mediated anti‐tumor application

open access: yesResponsive Materials, EarlyView.
Photo‐responsive CDs generate ROS to induce tumor cell pyroptosis, thereby stimulating antitumor immunity. Abstract Pyroptosis refers to a kind of lytic programmed cell death, characterized by the release of pro‐inflammatory cytokines during the process. Owing to its immune response stimulation ability, pyroptosis has garnered considerable attention in
Lingyun Li   +5 more
wiley   +1 more source

Immunohistochemical Expression of HLA Classes I and II in Neonatal Cholestatic Liver Disease. [PDF]

open access: yesIran J Pathol
Taie DM   +5 more
europepmc   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

open access: yesSmall, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

Applications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review

open access: yesSmart Molecules, EarlyView.
This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy